Ignite Creation Date:
2025-12-25 @ 3:28 AM
Ignite Modification Date:
2026-06-24 @ 12:52 PM
Study NCT ID:
NCT07080905
Status:
RECRUITING
Last Update Posted:
2025-12-17
First Post:
2025-07-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
Sponsor:
CSL Behring
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Hemophilia B | View |
Keywords: